SeQuent Please, a polymer less drug eluting balloon technology for treating patients suffering from coronary artery diseases, has been launched in in India by B Braun India Pvt Ltd.

SeQuent Please drug eluting balloon technology does not use polymer in its design. This polymer less technology makes it free of any risk of inflammatory reactions or late stent thrombosis.

“The polymer less factor of ‘SeQuent Please’ benefits the patient with fewer side effects. Also, it reduces the need of administering clopidogrel which is an oral anti platelet agent to inhibit blood clots in coronary artery disease. As a result the technology becomes cost effective for the patient, stated Dr Martin Unverdorben, M.D., Ph.D., Associate Professor of Medicine.

SeQuent Please drug eluting balloon technology respects normal contours of the vessel without stent and provides uniform drug delivery at the target site for faster healing, B Braun said in a press statement.

Indian population shows a genetic disposition to cardiac blockages due to plaque formation. Approximately 1,50,000 coronary artery disease patients are intervened by cardiologists, out of which approximately 25-30 % show instent restenosis specially in small vessel disease, bifurcation lesions & Diabetics, according Dr. Upendra Kaul, executive director – Academics, Escorts Heart Institute And Research Centre.

SeQuent Please drug eluting balloon technology will be commercially available in the Indian market, said Aditya Banerjee, Dy Country Head, Aesculap Division, B Braun (I) Pvt Ltd, while announcing the release of the stent in Kochi, Kerala, southern India.